Manojna Nimmagadda
Chicago, ILNPI 1922530112
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (39.9%), grants and food and beverage — rather than concentrated in one kind of arrangement. Abbott accounts for 62.7% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2024 at $26,096 and has fallen 61.7% since, to $9,983 in 2025.
Across 522 payments — averaging $135.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$44K
- Medtronic$14K
- Biotronik Inc.$9K
- Boston Scientific$1K
- Amgen$529
- Cardiva Medical, Inc.$349
- plus $1K from 11 others
What the payments were for
- Grants$22,50032%
- Travel & lodging$28,20440%
- Food & beverage$18,23426%
- Education$1,6842%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 192 | $44,256 |
| Medtronic(2 entities) | 197 | $13,748 |
| Biotronik Inc. | 44 | $9,240 |
| Boston Scientific | 21 | $1,312 |
| Amgen | 19 | $529 |
| Cardiva Medical, Inc. | 7 | $349 |
| Biosense Webster, Inc. | 9 | $326 |
| Astellas Pharma US Inc | 6 | $280 |
| Pfizer | 11 | $215 |
| Boehringer Ingelheim | 3 | $87 |
| Philips North America LLC | 2 | $67 |
| AstraZeneca | 3 | $54 |
| Bayer | 2 | $40 |
| E.r. Squibb & Sons, L.L.C. | 2 | $37 |
| Novo Nordisk | 2 | $35 |
| Vital Connect, Inc | 1 | $26 |
| Terumo Medical Corporation | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ENSITE PRECISION$10,180
- TACTICATH ABLATION CATHETER, SENSOR ENABLED$7,635
- ASSURITY$7,500
- Micra$2,540
- Acticor$2,166
- Edora$2,166
- Rivacor$2,166
- ENSITE$2,112
- BioMonitor$1,321
- Solia$1,321
- HeartMate Touch$1,036
- Sentus$964
- EnSite Precision Cardiac Mapping System$943
- Plexa$845
- GALLANT$701
- VersaCross Access Solution$390
- CardioMEMS HF System$277
- QDOT MICRO$147
- OCTARAY MAPPING CATHETER$132
- ACUITY Steerable$120
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 11 | $7,540 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $215 | $7,54011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in Illinoison file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.